As Amicus Therapeutics (FOLD) Valuation Rose, Tourbillon Capital Partners LP Has Raised by $42.54 Million Its Position; As Actuant (ATU) Share Price Declined, Vulcan Value Partners Has Cut Position by $21.79 Million

April 20, 2018 - By wolcottdaily

Actuant Corporation (NYSE:ATU) Logo

Jason Karp increased its stake in Amicus Therapeutics Inc (FOLD) by 1215.32% based on its latest 2017Q4 regulatory filing with the SEC. Tourbillon Capital Partners Lp bought 3.04M shares as the company’s stock rose 0.85% while stock markets declined. The hedge fund run by Jason Karp held 3.29M shares of the health care company at the end of 2017Q4, valued at $47.32 million, up from 250,000 at the end of the previous reported quarter. Tourbillon Capital Partners Lp who had been investing in Amicus Therapeutics Inc for a number of months, seems to be bullish on the $2.73 billion market cap company. The stock decreased 0.82% or $0.12 during the last trading session, reaching $14.52. About 695,681 shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 90.40% since April 20, 2017 and is uptrending. It has outperformed by 78.85% the S&P500.

Vulcan Value Partners Llc decreased its stake in Actuant Corp (ATU) by 52.54% based on its latest 2017Q4 regulatory filing with the SEC. Vulcan Value Partners Llc sold 871,443 shares as the company’s stock declined 7.93% with the market. The institutional investor held 787,207 shares of the industrial machinery and components company at the end of 2017Q4, valued at $19.92 million, down from 1.66M at the end of the previous reported quarter. Vulcan Value Partners Llc who had been investing in Actuant Corp for a number of months, seems to be less bullish one the $1.48 billion market cap company. The stock decreased 0.31% or $0.08 during the last trading session, reaching $24.42. About 97,780 shares traded. Actuant Corporation (NYSE:ATU) has declined 9.76% since April 20, 2017 and is downtrending. It has underperformed by 21.31% the S&P500.

Investors sentiment decreased to 1.29 in 2017 Q4. Its down 0.08, from 1.37 in 2017Q3. It fall, as 21 investors sold ATU shares while 38 reduced holdings. 19 funds opened positions while 57 raised stakes. 64.66 million shares or 3.05% more from 62.75 million shares in 2017Q3 were reported. Credit Suisse Ag accumulated 0% or 60,515 shares. Cipher Capital Ltd Partnership, a New York-based fund reported 69,180 shares. Proshare Advsr Ltd Liability has 11,096 shares for 0% of their portfolio. Blackrock Inc owns 7.54M shares or 0.01% of their US portfolio. Missouri-based Parkside Bank & Trust And Trust has invested 0% in Actuant Corporation (NYSE:ATU). Pinebridge Lp holds 0.04% or 65,039 shares in its portfolio. Balyasny Asset Ltd Com has 0% invested in Actuant Corporation (NYSE:ATU) for 32,567 shares. 14,292 were accumulated by Leucadia Natl. 712,661 were accumulated by Comml Bank Of Mellon. Vulcan Value Prns Ltd Limited Liability Company has 787,207 shares. Tower Ltd Liability Com (Trc) has 0.02% invested in Actuant Corporation (NYSE:ATU) for 6,201 shares. Cim Mangement Incorporated, a Pennsylvania-based fund reported 13,156 shares. Profund Advsrs Limited Liability Corp holds 0.01% in Actuant Corporation (NYSE:ATU) or 10,450 shares. 2.88 million were accumulated by Fuller & Thaler Asset Mgmt. Pzena Invest Limited Co accumulated 4.27 million shares or 0.53% of the stock.

Among 18 analysts covering Actuant (NYSE:ATU), 6 have Buy rating, 0 Sell and 12 Hold. Therefore 33% are positive. Actuant had 50 analyst reports since August 26, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Hold” rating in Wednesday, March 21 report. The stock of Actuant Corporation (NYSE:ATU) has “Market Perform” rating given on Tuesday, April 5 by BMO Capital Markets. Barclays Capital downgraded it to “Underweight” rating and $19 target in Monday, October 24 report. The firm earned “Neutral” rating on Thursday, October 8 by JP Morgan. The rating was maintained by KeyBanc Capital Markets with “Overweight” on Thursday, March 22. The firm earned “Hold” rating on Tuesday, July 25 by RBC Capital Markets. As per Monday, June 5, the company rating was maintained by RBC Capital Markets. BMO Capital Markets maintained the stock with “Market Perform” rating in Friday, August 18 report. On Friday, December 18 the stock rating was initiated by Acumen Capital with “Speculative Buy”. Stifel Nicolaus maintained the shares of ATU in report on Thursday, June 22 with “Hold” rating.

Analysts await Actuant Corporation (NYSE:ATU) to report earnings on June, 20. They expect $0.36 earnings per share, up 12.50% or $0.04 from last year’s $0.32 per share. ATU’s profit will be $21.85M for 16.96 P/E if the $0.36 EPS becomes a reality. After $0.13 actual earnings per share reported by Actuant Corporation for the previous quarter, Wall Street now forecasts 176.92% EPS growth.

Vulcan Value Partners Llc, which manages about $6.07B and $12.21 billion US Long portfolio, upped its stake in Cardinal Health Inc (NYSE:CAH) by 161,654 shares to 4.79 million shares, valued at $293.26M in 2017Q4, according to the filing. It also increased its holding in Navigators Group Inc (NASDAQ:NAVG) by 186,852 shares in the quarter, for a total of 1.14 million shares, and has risen its stake in Anthem Inc (NYSE:ANTM).

Tourbillon Capital Partners Lp, which manages about $1.12B and $2.70 billion US Long portfolio, decreased its stake in Alexion Pharmaceuticals Inc (Call) (NASDAQ:ALXN) by 400,000 shares to 650,000 shares, valued at $77.73 million in 2017Q4, according to the filing. It also reduced its holding in Sarepta Therapeutics Inc (Put) (NASDAQ:SRPT) by 370,400 shares in the quarter, leaving it with 1.10M shares, and cut its stake in Spdr S&P 500 Etf Tr (Put) (SPY).

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 22 analyst reports since August 18, 2015 according to SRatingsIntel. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Buy” rating given on Tuesday, March 8 by Janney Capital. Cowen & Co maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Tuesday, July 11 with “Buy” rating. The firm earned “Buy” rating on Tuesday, September 1 by Cowen & Co. JP Morgan maintained it with “Overweight” rating and $28 target in Tuesday, September 8 report. As per Sunday, June 25, the company rating was maintained by Cowen & Co. On Wednesday, May 18 the stock rating was initiated by Bank of America with “Buy”. Chardan Capital Markets upgraded the shares of FOLD in report on Monday, October 5 to “Buy” rating. As per Tuesday, August 18, the company rating was downgraded by Zacks. Goldman Sachs initiated it with “Neutral” rating and $10 target in Wednesday, March 30 report. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Buy” rating by Leerink Swann on Monday, August 31.

Investors sentiment decreased to 1.21 in Q4 2017. Its down 1.12, from 2.33 in 2017Q3. It dived, as 25 investors sold FOLD shares while 48 reduced holdings. 25 funds opened positions while 63 raised stakes. 197.59 million shares or 2.54% more from 192.70 million shares in 2017Q3 were reported. The British Columbia – Canada-based Pacad Inv Ltd has invested 0.01% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Omega Advsrs holds 100,000 shares. Numeric Invsts Ltd Limited Liability Company accumulated 0.02% or 192,431 shares. Alliancebernstein Lp holds 256,846 shares. Moreover, Natixis has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 36,911 shares. Aqr Management reported 229,666 shares stake. Parallax Volatility Advisers Lp reported 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Amer Grp owns 112,483 shares or 0.01% of their US portfolio. 164,100 were reported by State Of Wisconsin Board. Metropolitan Life Insurance Comm Ny reported 0.01% stake. Sg Americas Securities Ltd Com has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Moreover, Teacher Retirement Sys Of Texas has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Tiaa Cref Investment Mgmt Limited Liability Company has 529,668 shares. 34,900 were reported by Adams Diversified Equity Fund. Comml Bank Of Mellon owns 879,536 shares.

Since October 17, 2017, it had 3 insider purchases, and 14 insider sales for $4.83 million activity. PERCEPTIVE ADVISORS LLC also bought $4.55 million worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares. 10,000 Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares with value of $147,181 were sold by Baird William D III. Another trade for 9,366 shares valued at $140,490 was made by RAAB MICHAEL on Tuesday, January 2. Quimi Daphne also sold $117,723 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Tuesday, January 2. Andrews Kurt J. also sold $71,343 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares. 20,000 shares were sold by HAYDEN DONALD J JR, worth $300,002.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: